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Replication of the papillomavirus genome is initiated by the assembly of a complex between the viral E1 and
E2 proteins at the origin. The E1 helicase is comprised of a C-terminal ATPase/helicase domain, a central
domain that binds to the origin, and an N-terminal regulatory region that contains nuclear import and export
signals mediating its nucleocytoplasmic shuttling. We previously reported that nuclear accumulation of E1 has
a deleterious effect on cellular proliferation which can be prevented by its nuclear export. Here we have shown
that nuclear accumulation of E1 from different papillomavirus types blocks cell cycle progression in early S
phase and triggers the activation of a DNA damage response (DDR) and of the ATM pathway in a manner that
requires both the origin-binding and ATPase activities of E1. Complex formation with E2 reduces the ability
of E1 to induce a DDR but does not prevent cell cycle arrest. Transient viral DNA replication still occurs in
S-phase-arrested cells but surprisingly is neither affected by nor dependent on induction of a DDR and of the
ATM kinase. Finally, we provide evidence that a DDR is also induced in human papillomavirus type 31
(HPV31)-immortalized keratinocytes expressing a mutant E1 protein defective for nuclear export. We propose
that nuclear export of E1 prevents cell cycle arrest and the induction of a DDR during the episomal mainte-
nance phase of the viral life cycle and that complex formation with E2 further safeguards undifferentiated cells
from undergoing a DDR when E1 is in the nucleus.
Human papillomaviruses (HPVs) are small double-stranded
DNA viruses that infect the differentiating epithelium of the
skin or mucosa (reviewed in references 10 and 91). About 25
types infect the anogenital tract (6, 19), characterized either as
low-risk or high-risk types according to their association with
benign or malignant hyperproliferative lesions. Clinically,
low-risk HPV types cause benign warts while high-risk types
are associated with lesions that can progress to cancer (28,
56, 63, 86).
The HPV life cycle is dependent on the differentiation pro-
gram that keratinocytes undergo within a stratified epithelium.
Viral DNA replication is required during the three distinct
phases of the viral life cycle (reviewed in references 30 and 36).
Upon infection of cells from the basal layer of the epithelium,
the viral genome is established as a nuclear episome and is
replicated by up to 50 to 100 copies (reviewed in reference 30).
These episomes are then maintained at a constant copy num-
ber by low levels of replication in the lower layers of the
epithelium. During this maintenance phase, viral DNA repli-
cation is thought to occur only once per cell cycle, during S
phase, and in synchrony with replication of the host DNA (32).
Finally, as the infected keratinocytes reach the uppermost dif-
ferentiated layers of the epithelium, the copy number of the
viral episome is amplified to very high levels (reviewed in
reference 30), presumably through multiple rounds of replica-
tion in S-phase-arrested cells (23, 32). These episomes drive
the expression of the late capsid proteins (27) and become
encapsidated to form new virions, which are eventually shed
with the top layer of the epithelium.
Two viral proteins, E1 and E2, are required for replication
and amplification of the viral episome (reviewed in reference
74). Initiation of viral DNA replication relies on the capacity of
E2 to bind specific sequences within the viral origin of repli-
cation and to simultaneously interact with the viral helicase E1
(1, 3). Through these interactions, E2 recruits several mono-
mers of E1 to the viral origin (25, 26, 45, 50, 61, 82) and
facilitates their assembly into a functional double hexamer that
will unwind DNA ahead of the replication fork (64, 65, 77, 80,
81, 85) and serve as a platform for the assembly of host DNA
replication factors, such as RPA, polymerase -primase, and
topoisomerase I (12, 13, 29, 44, 48, 58).
The HPV E1 helicase can be divided into three main
functional regions. The C-terminal half of E1 comprises an
ATPase/helicase domain typical of superfamily III (31, 33), which
can self-assemble into hexamers and interact with E2, poly-
merase -primase, and topoisomerase I (12, 48, 75, 81, 82, 84).
The origin-binding domain (OBD) is located in the center of
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E1 and is required for dimerization and binding to the viral
origin (80). Together, the OBD and C-terminal domain are
sufficient to catalyze viral DNA replication in vitro but not in
vivo (2, 76; this study), thereby suggesting that the N-terminal
region of E1 has a regulatory role during viral DNA replication
in vivo. Many elements within the N-terminal region are re-
quired for efficient viral DNA replication in vivo (14, 52, 54).
Among these, a bipartite nuclear localization signal (NLS), a
Crm1-dependent nuclear export signal (NES), a cyclin E/A-
binding motif (CBM), and specific Cdk2 phosphorylation sites
(S92 and S106 in HPV type 31 (HPV31) and S89, S93, and
S107 in HPV11) have been shown to regulate the nucleocyto-
plasmic shuttling of E1 (18, 23, 46, 88). Recently, we showed
that the shuttling of E1 needs to be tightly regulated since
overaccumulation of this helicase in the nucleus inhibits cellu-
lar proliferation by causing cell cycle arrest in S phase (23). As
part of this study, we also demonstrated that the nuclear export
of E1 is required for the maintenance of the viral genome in
undifferentiated keratinocytes but not for its amplification in
differentiated cells. These findings led us to suggest that the
Crm1-dependent export of E1 serves to limit its nuclear
accumulation during the maintenance phase of the genome
in order to prevent cell cycle arrest. Conversely, blocking the
nuclear export of E1 in differentiated cells would create a
favorable environment for viral DNA amplification by increas-
ing the levels of E1 in the nucleus and blocking cells in S phase.
Cell cycle arrest is often the result of a cellular DNA damage
response (DDR) and activation of cell cycle checkpoints (re-
viewed in references 4 and 5). Interestingly, one of our groups
has recently reported that a DDR is activated in keratinocytes
immortalized with HPV and is required for the amplification of
the viral episome (53). Furthermore, the induction of a DDR
caused by the E1- and E2-dependent replication of integrated
HPV genomes has been shown to promote genomic instability
(35–37). Activation of a DDR can originate from two types of
DNA breakage: double-stranded and single-stranded breaks
(DSBs and SSBs, respectively). DSBs induce the activation of
the ataxia-telangiectasia mutated (ATM)-dependent pathway,
which is characterized by the phosphorylation of ATM and its
downstream effector kinase, Chk2. SSBs, however, lead to
the activation of the ATM and Rad3-related (ATR) path-
way, which results in the activation of the ATR kinase and
phosphorylation of its cognate downstream effector kinase,
Chk1. Upon their activation, both pathways trigger the activa-
tion of checkpoints that block cell cycle progression and facil-
itate DNA repair (reviewed in references 4 and 5).
In this study, we have demonstrated that the ability of E1 to
block cell cycle progression and inhibit cellular proliferation is
conserved among papillomaviruses and is dependent on the
activities of the E1 OBD and ATPase/helicase domain. We
have determined that E1-expressing cells are arrested in early
S phase and interestingly that this cell cycle block is accompa-
nied by the activation of a DDR and specifically of the ATM
pathway. We have shown that high concentrations of E2 can
prevent the induction of a DDR by E1 but cannot relieve its
inhibitory effect on cell cycle progression. We also have dem-
onstrated that transient viral DNA replication neither requires
nor is affected by this DDR. Finally, we have provided evi-
dence, using keratinocytes which express a nuclear export-
defective E1 from the viral episome, that overaccumulation of
E1 in the nucleus is sufficient to induce a DDR. We suggest
that the ability of E1 to cause cell cycle arrest and to induce a
DDR is prevented by nuclear export during the episomal main-
tenance phase of the viral life cycle but not in differentiated
cells, where a DDR has been shown to facilitate amplification
of the viral genome (53).
MATERIALS AND METHODS
Plasmid construction. The plasmid used to express HPV31 E2 fused to a
3-Flag (3F) epitope and the plasmids used in the HPV31 transient DNA repli-
cation assay have been described previously (24). The red fluorescent protein
(RFP)-PCNA expression plasmid was a kind gift of M. Cristina Cardoso (72).
Plasmids expressing HPV31 E1 fused to enhanced yellow fluorescent protein
(EYFP), as well as E1 from HPV16, HPV11, and bovine papillomavirus type 1
(BPV-1) fused to green fluorescent protein (GFP), were previously described
(14, 22). The plasmid expressing HPV31 E1 fused to GFP was constructed by
inserting a PCR fragment that contains a modified E1 open reading frame
(ORF), bearing a silent mutation that inactivates an internal splicing donor site,
between the XhoI and BamHI sites of plasmid pGFP2-C2 (BioSignal Packard-
Perkin-Elmer). Plasmids expressing amino acids 1 to 159 and 1 to 332 of HPV31
E1 fused to EYFP were constructed by introducing the appropriate E1 PCR
fragment between the XhoI and BamHI sites of plasmid pEYFP-C1 (Clontech).
Plasmids expressing E1 fragments that lack the E1 NLS (amino acids 160 to 332,
160 to 629, and 332 to 629) as fusions to EYFP and to the NLS of SV40 large T
antigen (LTA) were constructed similarly, with the exception that the PCR
fragments were introduced between the BamHI and SalI sites of plasmid AB-
2531, which expresses EYFP fused at its C terminus to the SV40 LTA NLS
(PKKKRKV). Plasmid AB-2531 was constructed by inserting a PCR fragment
encoding the SV40 LTA NLS between the BglII and EcoRI sites of plasmid
pEYFP-C1 (Clontech). Amino acid substitutions in the origin binding (K265A/
R267A) and ATPase (K463A) domains of HPV31 E1 were introduced by mu-
tagenesis of the EYFP-E1 expression plasmid using the QuikChange kit (Strat-
agene). All DNA constructs were verified by sequencing. Further details on their
construction will be provided upon request.
Cell culture, transfection, and whole-cell extract preparation. The human
cervical carcinoma cell lines C33A and HeLa, ATM-deficient line (primary skin
fibroblasts, HDSF, AG04405A; Coriell Institute), as well as the osteosarcoma
U2OS line, were grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), 50 U/ml of penicillin, 50 g/ml
streptomycin, and 2 mM L-glutamine. Human foreskin keratinocytes (HFKs)
that have been immortalized with either the HPV31 wild type (WT) or NES
mutant genomes were described previously (23). These cells lines were main-
tained in KGM (Clonetics) or in E medium in the presence of mitomycin C
(Boehringer Mannheim)-treated fibroblast feeders. Transfections of C33A cells
were performed using the Lipofectamine 2000 reagent (Invitrogen) according to
the manufacturer’s protocol. Whole-cell extracts were prepared 24 h posttrans-
fection by resuspension of the transfected C33A cells in lysis buffer (phosphate-
buffered saline [PBS] supplemented with 0.1% Triton X-100, protease and phos-
phatase inhibitors [10 g of antipain, 2 g of leupeptin, 1 g of pepstatin, and 2
g of aprotinin/ml, 1 mM phenylmethylsulfonyl fluoride, 50 mM NaF, and 1 mM
orthovanadate {Na3VO4}]) and freezing at 80°C overnight. Cell extracts were
thawed and boiled in Laemmli buffer (42) prior to SDS-PAGE.
Confocal fluorescence microscopy. C33A cells (8  105) were transfected
with the amount of EYFP-31E1 expression plasmid needed and grown on cov-
erslips. When indicated, 3F-31E2 WT and a plasmid containing the viral origin
of replication were cotransfected with EYFP-31E1. Twenty-four hours posttrans-
fection, cells were fixed with 4% formaldehyde. For the detection of H2AX,
pATM, pChk2, and pChk1, cells were treated as described in the next section.
Otherwise, cells were directly permeabilized with 0.2% Triton X-100, and their
DNA was stained with a solution of TO-PRO-3 (1 M) (Molecular Probes).
Cells were mounted using Vectashield mounting medium (Vector Laboratories).
Images were acquired using a LSM710 confocal laser coupled to an Axiovert 100
M inverted scanning microscope (Zeiss) and analyzed using the ZEN 2009 LE
software program.
Immunofluorescence. Twenty-four hours posttransfection, cells were perme-
abilized with 0.5% Triton X-100 for 10 min at 4°C, treated with 50 mM NH4Cl
in PBS for 10 min at room temperature, and then blocked with PBS containing
10% bovine serum albumin (BSA) for 3 to 4 h at room temperature. Cells were
then incubated with a dilution of the primary antibody (1:500 for detection of
H2AX, pATM, and pChk2; 1:200 for pChk1) overnight at 4°C. After two
washes in PBS-BSA, cells were incubated with the secondary antibody (anti-
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mouse Alexa 633 or anti-rabbit Alexa 633) for 30 min at room temperature.
Where indicated, DNA was stained with a solution of 4,6-diamidino-2-phenylin-
dole (DAPI) (1 g/ml) (catalog no. D1306; Invitrogen). Cells were mounted
using Vectashield mounting medium (Vector Laboratories). Images were ac-
quired as described above.
Antibodies. (i) Immunofluorescence. Phospho-H2AX Ser 139 (H2AX) and
phospho-ATM Ser1981 (pATM) were detected using mouse monoclonal anti-
body from Millipore (clone JBW301, catalog no. 05-636; Upstate) and Rockland
(catalog no. 200-301-400), respectively, and then with an Alexa Fluor 633-con-
jugated goat anti-mouse secondary antibody from Molecular Probes (catalog no.
A21050). Similarly, phospho-Chk2 Thr 68 (pChk2) and phospho-Chk1 Ser 345
(pChk1) were detected using rabbit polyclonal antibodies from Cell Signaling
(catalog no. 2661 and 2348, respectively) and then with an Alexa Fluor 633-
conjugated goat anti-rabbit secondary antibody from Molecular Probes (catalog
no. A21070).
(ii) Western blotting. GFP and EYFP fusion proteins were detected using a
mixture of two mouse monoclonal antibodies purchased from Roche (catalog no.
11814460001), while -tubulin was detected using a mouse monoclonal antibody
from Sigma-Aldrich (catalog no. T0426). For Western blot analysis, proteins
were transferred onto polyvinylidene difluoride membranes and detected using a
horseradish peroxidase-conjugated sheep anti-mouse secondary antibody from
GE Healthcare (catalog no. NA931) and an enhanced chemiluminescence de-
tection kit (GE Healthcare).
Transient HPV DNA replication assay. Transient HPV31 DNA replication
was performed as described previously (24) but using EYFP-31E1 instead of
Flag-tagged E1 (3F-31E1). Briefly, 5  104 C33A cells were transfected with
four plasmids encoding, respectively, EYFP-31E1, 3F-31E2, the minimal origin
of DNA replication together with a firefly luciferase (Fluc) reporter gene
(pFLORI31), and Renilla luciferase (Rluc) (pRL). Under standard conditions,
1.25, 2.5, and 5 ng of E1 were used along with a constant quantity of the other
plasmids (1) (10 ng of 3F-31E2, 2.5 ng of pFLORI31, and 0.5 ng of pRL).
When indicated, 2, 4, and 8 of 3F-31E2 (20, 40, and 80 ng, respectively) and
pFLORI31 (5, 10, and 20 ng, respectively) were used. For all conditions, repli-
cation of the origin-containing plasmid was quantified 24 or 72 h posttransfection
by measuring the levels of firefly and Renilla luciferase activities using the Dual-
Glo luciferase assay system (Promega). E1 mutants were analyzed in duplicate in
two separate experiments.
Cell cycle analysis. When several conditions were analyzed for a given trans-
fected population (asynchronous, mimosine block and release in nocodazole),
cells were prepared as previously described (23). When a single condition was
analyzed (asynchronous), 8  105 C33A cells were transfected with 1 g of the
indicated plasmid(s) in 6-well plates and directly prepared for cell cycle analysis
24 or 48 h later. Briefly, cells were trypsinized and either fixed and stained with
a solution containing 50 g/ml of propidium iodide (PI) (catalog no. P4170;
Sigma-Aldrich) or stained directly using fresh medium supplemented with 6.3
g/ml of Hoechst (catalog no. B2261; Sigma-Aldrich) and 5 mM verapamil
(catalog no. V4629; Sigma-Aldrich) for 30 min at 37°C. The DNA content of
EYFP-expressing cells was determined by flow cytometry on a FACScan (PI
staining) or FACS BD LSR (Hoechst staining) flow cytometer using the Cell-
quest Pro software program (BD). Cell cycle distribution was further analyzed
and quantified using the FlowJo (v8.1) and ModFit LT software programs,
respectively. Specifically, the synchronization wizard within this software was
used to construct a model for the cell cycle distribution of C33A cells expressing
EYFP alone (i.e., control cells). In this model, the G1 and G2/M peaks are fixed
manually and locked for further analysis. Next, the algorithm within Modfit was
used to model the S phase (i.e., the region between the G1 and G2/M peaks) to
a rectangle model and to separate it in 3 distinct compartments with equal
spacing. These compartments were fixed and used to determine the percentages
of cells in early, mid-, and late S phase. Once fixed, the same model was used to
determine the percentages of cells in G1, early S, mid-S, late S, and G2/M phase
for cells expressing EYFP-E1. High-EYFP-expressing cells were excluded from
the analysis of cells released in nocodazole since control cells expressing high
levels of EYFP and GFP alone were unable to reenter the cell cycle (data not
shown).
Quantification of H2AX and incorporation of bromodeoxyuridine (BrdU). (i)
H2AX analysis. C33A cells (8  105) were transfected with 1 to 2 g of the
indicated plasmid(s) in 6-well plates. Twenty-four hours later, cells were
trypsinized and fixed in 70% ethanol overnight at 20°C. Fixed cells were
permeabilized in PST (PBS supplemented with 4% FBS and 0.1% Triton X-100)
for 10 min on ice. Cells were subsequently incubated with the primary antibody
(H2AX) diluted to 1:500 in PST for 2 h at room temperature. Cells were then
washed twice with PBS-2% FBS solution and incubated with a 1:400 dilution of
the secondary antibody (mouse Alexa Fluor 633) for 1 h at room temperature.
Finally, cells were washed and resuspended in PBS-2% FBS solution for fluo-
rescence-activated cell sorter (FACS) analysis. Since the induction of H2AX is
correlated with the levels of expression of E1, the EYFP signal was analyzed
separately for low-, medium-, and high-EYFP-expressing cells. Fluorescence
intensities ranging from 5 to 20 were considered low, those from 20 to 115 were
considered medium, and those from 115 to 1,000 were considered to indicate
high-EYFP-expressing cells.
(ii) Incorporation of BrdU. BrdU incorporation was measured using the allo-
phycocyanin (APC) BrdU flow kit from BD Pharmingen (catalog no. 522598)
according to the manufacturer’s recommendations. Briefly, 24 h posttransfection,
cells were pulsed with 10 M BrdU for 1 h and then fixed, permeabilized, and
treated with DNase to enable access of the APC antibody to the BrdU incorpo-
rated in the DNA. Next, cells were stained with anti-BrdU-APC and 7-amino-
actinomycin D (7-AAD) and analyzed by FACS.
(iii) Flow cytometry analysis. The H2AX, BrdU, and 7-AAD contents of
EYFP-expressing cells were determined by flow cytometry on a FACS BD LSR
flow cytometer using the Cellquest Pro software program (BD). H2AX and
BrdU were further analyzed and quantified using the FlowJo (v8.1) software
program, while cell cycle distribution was analyzed by FlowJo and quantified
using ModFit LT software. When indicated, hydroxyurea (HU) (2 mM) or
aphidicolin (Aph) (5 g/ml) was added to the transfected cells 4 h posttransfec-
tion.
Colony formation assay. C33A cells (8  105) were transfected with 1 g of
the indicated plasmid in a 6-well plate. Twenty-four hours posttransfection, cells
were trypsinized and seeded on 100-mm plates in fresh medium supplemented
with 500 g/ml of G418 or 15 g/ml of bleomycin (Bleocin; EMD Millipore
catalog no. 203408). Antibiotic selection was maintained for a period of approx-
imately 3 weeks. Cells were then fixed for 10 min in cold methanol and stained
for 2 min with methylene blue (1% [wt/vol] in 60% MeOH-H2O).
RESULTS
The ability to arrest S-phase progression is a conserved
feature of papillomavirus E1. We have recently reported that
nuclear accumulation of HPV31 E1 inhibits the proliferation
of transfected C33A cells by arresting them in S phase (23). To
determine if this activity is conserved among papillomavirus E1
proteins, we tested the ability of two other E1 proteins, from
HPV11 and BPV, to inhibit proliferation of C33A cells in a
colony formation assay (CFA). These experiments, which were
performed with GFP-E1 fusion proteins expressed from a vec-
tor containing a Zeocin resistance gene, revealed that the
HPV11 and BPV E1 proteins were as good as HPV31 E1 at
inhibiting colony formation (Fig. 1A). To determine if this
inhibition was due to an arrest in S phase, we analyzed the cell
cycle distribution of C33A cells transiently expressing these
GFP-E1 proteins (i.e., of GFP-positive cells). As anticipated,
we found that HPV11 and BPV E1 also led to an accumulation
of cells in S phase (Fig. 1B and C and Table 1), similarly to
HPV31 E1 and unlike GFP alone, which was used as a negative
control. To further characterize this cell cycle arrest, we tested
if E1-expressing cells were able to resume cell cycle progres-
sion following a block in G1/S by mimosine. In these experi-
ments, cells were released from the mimosine block into me-
dium containing nocodazole to prevent their progression past
the G2/M boundary. Consistent with the results obtained with
asynchronous cells, the majority of E1-expressing cells were
unable to progress to G2/M, although 73% of the GFP-trans-
fected cells were able to do so (Fig. 1B and Table 2). Western
blotting showed that HPV31 and -11 E1 were expressed at
comparable levels. As for BPV E1, it was expressed at slightly
higher levels but also showed an increase in low-molecular-
weight degradation products (Fig. 1D). Collectively, the results
presented above suggest that the capacity of E1 to prevent
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cellular proliferation by blocking S-phase progression is a con-
served activity of papillomavirus E1.
The origin-binding and helicase domains of E1 are neces-
sary and sufficient to inhibit cellular proliferation. To deter-
mine which domains of E1 are required for inhibiting cellular
proliferation, we performed colony formation assays with a
series of HPV31 E1 truncations spanning the N-terminal re-
gion, the OBD, and/or the C-terminal enzymatic domain (Fig.
2A). All truncations were fused to EYFP, and those lacking the
N-terminal region of E1 were fused to the SV40 large T anti-
gen NLS. The addition of the NLS was necessary since we
previously showed that the antiproliferative effect of E1 is
dependent on its nuclear accumulation (23). The results in Fig.
2B show that the two N-terminal fragments of E1 lacking the
ATPase/helicase domain (E1 amino acids [aa] 1 to 159 and 1 to
TABLE 2. Cell cycle distribution of GFP- and EYFP-expressing









GFP-HPV31 E1 74 26
GFP-HPV11 E1 67 33
GFP-BPV1 E1 67 33
GFP-HPV16 E1 WT 70 30
GFP-HPV16 E1 ATPase 39 61
EYFP 23 77
EYFP-31E1 WT 58 42
EYFP-31E1 OBD 34 66
EYFP-31E1 ATPase 35 65
EYFP-31E1 NES 64 36
EYFP-31E1 NES/OBD 35 65
EYFP-31E1 NES/ATPase 41 59
a Five thousand cells positively stained with Hoechst or doubly stained with
Hoechst and EYFP/GFP were selected for mock- and EYFP/GFP-transfected
cells, respectively.
b The percentage of cells that resumed cell cycle progression following their
release from a G1/S block with mimosine was quantified by counting the numbers
of cells in mid- and late S phase and in G2/M phase.
FIG. 1. E1 proteins from different papillomavirus types inhibit cel-
lular proliferation. (A) Colony formation assays (CFA). C33A cells
were transfected with the indicated GFP-E1 expression vector (also
containing a Zeocin resistance gene). Following 4-weeks’ selection in
bleomycin, colonies were stained with methylene blue. (B) Cell cycle
analysis. C33A cells transiently expressing the indicated GFP-E1 or
GFP were trypsinized 48 h posttransfection, and their DNA was
stained with Hoechst stain and analyzed by flow cytometry. For each
condition, the cells were either grown asynchronously (Asynchr.) or
synchronized with mimosine for 24 h and then released in nocodazole
for an additional 24 h (Released in Nocodazole). The cell cycle profile
of each sample is shown as a histogram and quantified in Tables 1 and
2. (C) Graphical representation of the cell cycle distributions shown in
panel B. ES, MS, and LS stand for early, mid-, and late S phase,
respectively. (D) Western blot analysis of total protein extracts pre-
pared from transfected C33A cells expressing the GFP-E1 proteins of
the various papillomaviruses used in this study. E1 proteins were de-
tected using an anti-GFP antibody, and tubulin (Tub.) was used as a
loading control.








Mock 32 53 15 47 26 26
GFP 52 34 14 56 21 24
GFP-HPV31 E1 9 87 4 85 14 1
GFP-HPV11 E1 33 61 7 75 18 7
GFP-BPV1 E1 39 55 6 76 18 5
GFP-HPV16 E1 WT 16 81 3 78 17 5
GFP-HPV16 E1 ATPase 43 44 14 61 23 16
EYFP 43 43 14 47 30 23
EYFP-31E1 1-629 24 72 4 75 19 6
EYFP-31E1 1-159 49 40 11 48 25 28
EYFP-31E1 1-332 49 40 11 50 30 20
EYFP-NLS 46 39 15 44 28 28
EYFP-NLS-31E1 160-332 45 43 12 47 28 26
EYFP-NLS-31E1 160-629 37 59 4 66 22 12
EYFP-NLS-31E1 332-629 45 44 11 45 27 27
EYFP 38 48 14 54 25 21
EYFP-31E1 WT 20 74 6 77 16 7
EYFP-31E1 OBD 38 49 13 53 24 22
EYFP-31E1 ATPase 37 55 9 64 22 15
EYFP-31E1 NES 18 75 7 88 7 5
EYFP-31E1 NES/OBD 44 44 12 55 25 20
EYFP-31E1 NES/ATPase 40 44 16 61 25 14
a Five thousand cells positively stained with Hoechst stain or doubly stained
with Hoechst stain and EYFP/GFP were selected for mock- and EYFP/GFP-
transfected cells, respectively.
b The percentage of cells estimated to be in the early (E), mid (M)-, or late (L)
S phase according to the Modfit software program.
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332) were unable to inhibit cellular proliferation. Accordingly,
neither fragment had an effect on cell cycle progression (Fig.
2B and Table 1). In contrast, the E1 fragment comprised of the
OBD and ATPase/helicase domain (E1 aa 160 to 629) was
capable of preventing cellular proliferation and cell cycle pro-
gression to an extent similar to that of wild-type (i.e., full-
length) E1 (Fig. 2B and Table 1). Neither the OBD nor the
ATPase/helicase domain on its own was capable of inhibiting
proliferation or cell cycle progression. All truncated proteins
were properly localized to the nucleus and expressed at the
correct molecular weight, as determined by confocal fluores-
cence microscopy and Western blotting (data not shown). In-
terestingly, whereas the E1 fragment spanning the OBD and
ATPase/helicase domain (E1 aa 160 to 629) could inhibit cel-
lular proliferation, it could support only very low levels of
transient DNA replication (Fig. 2C). From these results, we
conclude that the OBD and ATPase/helicase domain of E1 are
necessary and sufficient to inhibit cellular proliferation and cell
cycle progression and consequently that none of the previously
described interactions of the N-terminal domain of E1 with
cellular proteins such as p80 (14) and cyclin E/A-Cdk2 (23, 46)
are required for this antiproliferative effect (Fig. 2A). Finally,
these results show that this effect is also independent of the
capacity of E1 to efficiently replicate DNA.
The origin-binding and ATPase activities of E1 are required
for arresting S-phase progression. To substantiate the results
presented above, we performed colony formation assays
with EYFP-31E1 mutant proteins carrying amino acid sub-
stitutions that abrogate the origin-binding (OBD mutant;
K265A/R267A) (80, 81) or ATPase (ATPase mutant; K463A)
activity (81, 84) of E1. The results presented in Fig. 3A show
that both E1 mutants failed to inhibit cellular proliferation.
However, we observed by fluorescence microcopy that the E1
OBD mutant was not entirely localized to the nucleus, in
contrast to the wild type and the ATPase E1 mutant, since it
was present in both the nucleus and cytoplasm in approxi-
mately 15% of the transfected cells (data not shown). To pre-
vent cytoplasmic accumulation of the E1 OBD mutant, we
generated a version lacking the nuclear export signal (NES)
and confirmed that it was entirely nuclear (data not shown).
For comparison, we also used NES-defective versions of the
ATPase mutant and of wild-type E1. When tested in CFAs,
both the OBD and ATPase mutant lacking the NES failed to
inhibit colony formation, thus confirming that the origin-bind-
ing and ATPase activities of E1 are required for preventing
cellular proliferation (Fig. 3A). When analyzed by Western
blotting, the NES/OBD mutant was reproducibly found to be
expressed at lower levels than the wild-type protein (Fig. 3C).
To ensure that the inability of this mutant to prevent cellular
proliferation was not due to its lower expression, we analyzed
the cell cycle distribution of EYFP-E1-expressing cells by flow
cytometry, since this technique allows the comparison of cells
expressing similar levels of EYFP fluorescence. Figure 3B
shows that the E1 OBD and ATPase mutants were unable to
prevent S-phase progression, as determined by the ability of
cells expressing these proteins to progress to G2/M upon re-
lease from a mimosine block (Fig. 3B and Table 1 and 2). All
together, these results indicate that the origin-binding and
enzymatic activities of E1 are both required for arresting cells
in S phase.
To test the generality of these findings, we repeated these
experiments with HPV16 E1 fused to GFP. As observed for
BPV, HPV11, and HPV31 E1, we found that HPV16 E1 was
able to inhibit cellular proliferation by imposing an S-phase
arrest (Tables 1 and 2 and data not shown). Furthermore, we
determined that these antiproliferative effects of E1 could be
abrogated by the mutation of its ATP-binding site (Table 1 and
2 and data not shown) (87). Thus, the enzymatic activity of
HPV16 E1 is also required for its growth-inhibitory effects,
similar to what was observed for HPV31 E1.
FIG. 2. The OBD and ATPase/helicase domain of E1 are both
required for its antiproliferative activity. (A) Schematic representation
of HPV31 E1 truncations used in this analysis, highlighting the loca-
tion of the p80-binding site (aa 10 to 40), the caspase-3/7 cleavage site,
the shuttling module (aa 85 to 125), the origin-binding domain (OBD),
and the ATPase/helicase domain. E1 fragments lacking the shuttling
module were fused to the SV40 large T antigen nuclear localization
signal (NLS). (B) Colony formation assay and cell cycle analysis. CFA
and cell cycle analysis were done essentially as described in the legend
for Fig. 1 with the exception that cells were selected in G418-contain-
ing medium for 3 weeks before staining the colonies with methylene
blue. (C) Transient DNA replication activities of E1 truncations. The
DNA replication activity of each E1 fragment was determined using
1.25, 2.5, and 5 ng of expression vector 72 h posttransfection. Repli-
cation activities are reported as a percentage of the Fluc/Rluc ratio
obtained with the 5 ng of the 1–629 E1 expression vector. Error bars
represent standard deviations. Cells transfected with EYFP or EYFP-
NLS only were used as negative controls.
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E1 inhibits the proliferation of different cell lines. Next, we
investigated if E1 could also prevent the proliferation of cell
lines other than C33A. We tested its effect in HeLa cells, which
express HPV18 E6 and E7, and in U2OS cells, which in con-
trast to C33A cells express wild-type p53. As shown in Fig. 4,
EYFP-31 E1 was able to inhibit the proliferation of HeLa and
U2OS cells to an extent similar to that with C33A cells. Im-
portantly, proliferation of all three cell lines was not affected by
the E1 NES/OBD and NES/ATPase mutants, thus suggesting
that the mechanism by which E1 affects cellular proliferation is
the same in each cell line. We then characterized the antipro-
liferative effect of E1 by flow cytometry and determined that
S-phase progression was blocked in all three cell lines express-
ing the wild type but not the mutant proteins (Fig. 4 and Table
3). Note that in these experiments, DNA content was mea-
sured by propidium iodide (PI) staining since Hoechst staining
was found to be deleterious to HeLa and U2OS cells (data not
shown). Consistent with the ability of E1 to induce a cell cycle
FIG. 3. Amino acid substitutions in the origin-binding and
ATPase domains of E1 abolish its antiproliferative activity. (A and
B) CFAs (A) or cell cycle analysis (B) of cells transfected with
EYFP alone or the indicated EYFP-E1 constructs carrying amino
acid substitutions in the OBD, ATPase domain, and NES, as de-
scribed in the text. For CFAs, cells were selected in G418-contain-
ing medium before staining. Cell cycle analyses were performed as
described for Fig. 1. (C) Western blot analysis in which E1 proteins
were detected using an anti-GFP antibody (-GFP) and tubulin was
used as a loading control (-Tub.).
FIG. 4. E1 inhibits cellular proliferation in p53-positive and
-negative cell lines. CFAs and cell cycle distributions of EYFP- and
EYFP-E1-transfected C33A, HeLa, or U2OS cells. CFA were per-
formed in G418-containing medium. Cell cycle distributions were
determined 24 h posttransfection using cells stained with propidium
iodide. Results are represented as histograms here and are quanti-
fied in Table 3.








Mock C33A 47 31 22 48 32 19
EYFP 50 29 21 48 34 17
EYFP-31E1 WT 21 70 9 86 14 0
EYFP-31E1 NES 25 66 9 88 12 0
EYFP-31E1 NES/OBD 64 24 12 50 33 17
EYFP-31E1 NES/ATPase 32 51 17 84 12 4
Mock HeLa 47 43 10 63 21 16
EYFP 57 36 8 64 19 17
EYFP-31E1 WT 33 65 2 80 18 2
EYFP-31E1 NES 38 58 4 78 19 3
EYFP-31E1 NES/OBD 60 33 7 52 33 15
EYFP-31E1 NES/ATPase 58 37 5 65 27 8
Mock U2OS 37 39 24 51 49 0
EYFP 32 44 24 59 41 0
EYFP-31E1 WT 35 54 11 83 17 0
EYFP-31E1 NES 27 65 8 78 22 0
EYFP-31E1 NES/OBD 45 43 12 58 37 5
EYFP-31E1 NES/ATPase 42 46 12 59 37 4
a Five thousand cells positively stained with propidium iodide (PI) or doubly
stained with PI and EYFP were selected for mock- and EYFP-transfected cells,
respectively.
b The percentage of cells estimated to be in the early (E), mid (M), or late (L)
S phase according to the Modfit software program.
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arrest in HeLa cells, we found that coexpression of HPV31 E6
and/or E7 in C33A cells did not prevent the deleterious effect
of EYFP-31E1 on cell cycle progression (data not shown).
Together, the results presented above indicate that the ability
of E1 to inhibit S-phase progression and cellular proliferation
is independent of the expression of E6 and E7 and that of p53
(68).
E1 arrests cells in early S phase. The flow cytometry results
presented above suggested that E1-expressing cells accumulate
in S phase. To confirm these results by an alternative method,
we investigated the effect of E1 on the assembly of PCNA foci,
whose size increases from early to late S phase (62). As can be
seen in Fig. 5A, large PCNA foci were never detected in cells
expressing wild-type EYFP-31E1 but could be readily observed
in cells expressing the NES/OBD E1 mutant. These results
suggest that cells expressing wild-type E1 fail to reach the
end of S phase. To pinpoint the position in S phase in which
E1-expressing cells were arrested, we set out to measure their
capacity to carry out DNA synthesis (by BrdU incorporation)
as a function of their position in the cell cycle (determined by
7-AAD staining). First, we determined by flow cytometry the
percentage of E1-expressing cells that could incorporate BrdU
at 24, 48, and 72 h posttransfection, following a 1-h pulse-
labeling period. As anticipated, BrdU incorporation gradually
decreased over time in cells expressing wild-type E1, consistent
with the induction of an S-phase arrest, but not in those ex-
pressing the E1 NES/OBD and NES/ATPase mutants (Fig.
5B). On the basis of these findings, we decided to measure
BrdU incorporation as a function of the cell cycle at 24 h
posttransfection. This analysis revealed that cells expressing
either a wild-type or NES mutant E1 protein could incorporate
BrdU in early S phase only. This was in contrast to the control
cells (mock or EYFP transfected) or cells expressing the E1
NES/OBD or NES/ATPase mutant (Fig. 5C). As additional
controls, we confirmed that the BrdU incorporation profile of
E1-expressing cells was similar to that of EYFP-transfected
cells treated with the DNA synthesis inhibitors aphidicolin and
hydroxyurea (Fig. 5C) (40, 57). Collectively, the results pre-
sented above indicate that E1 arrests cell cycle progression in
early S phase.
E1 induces a DNA damage response and activates the ATM
pathway. Since inhibition of cell cycle progression can be in-
duced by a DNA damage checkpoint response, we investigated
if E1 can trigger the phosphorylation of histone H2AX on
serine 139 (H2AX), a hallmark of a DNA damage response
(DDR) (9, 49, 59, 60). We examined the presence of H2AX
in cells expressing EYFP-E1 by confocal immunofluorescence
microscopy. As a positive control, we treated untransfected
cells with a 50 M concentration of the topoisomerase II
inhibitor etoposide for 24 h in order to induce a DDR (70). As
shown in Fig. 6A, etoposide treatment resulted in a robust
induction of H2AX compared to results for untreated cells
(Mock). A similar induction of H2AX was observed in cells
expressing wild-type E1 but not in those expressing either
EYFP alone, an E1 mutant that accumulates in the cytoplasm
(NLS), or nuclear E1 mutants defective for origin binding or
ATPase activity (Fig. 6A). Interestingly, we consistently ob-
served that the E1 NES/ATPase mutant protein weakly acti-
vates H2AX, perhaps because this mutant protein retains the
ability to bind DNA through its intact ODB (see Discussion).
The induction of H2AX by HPV31 E1 was also observed in
HeLa and U2OS cells, indicating that it is independent of E6,
E7, and p53 (data not shown). Finally, evidence linking the
induction of a DDR with cell cycle arrest came from the ob-
servation that among the different HPV31 E1 fragments char-
FIG. 5. E1 arrests cell cycle progression in early S phase. (A) Cel-
lular localization of RFP-PCNA in transfected cells expressing either
the wild type or an origin-binding-defective E1 protein. Twenty-four
hours posttransfection, cells were fixed, mounted, and visualized by
40 fluorescence confocal microscopy. Nuclei (DNA) were stained
with DAPI. Cells containing large PCNA foci (such as the one
indicated by the white arrow) were quantified and are reported on
the right side of the panel as a percentage of the total number of
RFP-PCNA-expressing cells. (B) BrdU incorporation. Twenty-four,
forty-eight, and seventy-two hours posttransfection, cells expressing
EYFP or EYFP-E1 wild-type or NES/OBD or NES/ATPase mutant
proteins were pulsed for 1 h with 10 M BrdU. The percentage of cells
that incorporated BrdU was then determined by flow cytometry and is
reported in the histogram. (C) BrdU incorporation throughout the cell
cycle. Cells expressing EYFP or EYFP-E1 wild type or the indicated
mutant proteins were pulsed with BrdU 24 h posttransfection and
analyzed as described for panel B. In addition, cells were stained with
7-AAD to measure their DNA content. For each sample, BrdU incor-
poration is represented as a function of DNA content (cell cycle
distribution) in a scatter plot. Boxes indicate the populations of cells in
G1, S, and G2. EYFP-transfected cells treated with hydroxyurea (HU)
and aphidicolin (Aph) were used as controls.
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acterized in Fig. 2, only those that caused cell cycle arrest were
able to induce the phosphorylation of H2AX (Fig. 6B).
The ability of E1 to induce a DDR appears to be conserved
among papillomaviruses, since H2AX was also detected in
cells expressing GFP-E1 from HPV11, HPV16, and BPV (Fig.
7A). In a time course experiment, we found that the expression
of HPV31 EYFP-E1 and the induction of H2AX could be
detected as early as 6 and 12 h posttransfection and followed
similar kinetics, consistent with H2AX being triggered soon
after expression of E1 (Fig. 7B). Since DNA damage is known
to induce the activation of the ATM or ATR checkpoints,
depending of the type of DNA lesions created (reviewed in
references 38 and 90), we investigated which of these two DDR
pathways was induced by E1. Specifically, we monitored the
activation of key components of the ATM and ATR pathways
by immunofluorescence microscopy. Activation of the ATM
pathway was assessed by detection of phosphoserine 1981 of
ATM (pATM) and, in separate experiments, phosphothreo-
nine 68 of Chk2 (pChk2). Activation of the ATR pathway was
monitored using an antibody against phosphoserine 345 of
Chk1 (pChk1). As shown in Fig. 7C and D, the levels of both
pATM and pChk2 were increased in cells expressing wild-type
E1 to an extent similar to that in cells treated with etoposide,
used as a positive control. As anticipated, cells expressing the
NES/OBD or NES/ATPase E1 mutant or expressing EYFP
alone showed significantly reduced levels of these markers
(Fig. 7C and D and data not shown). In contrast, pChk1 was
detected in only a few E1-expressing cells, unlike the case with
cells treated with etoposide or hydroxyurea, which were used
as positive controls (Fig. 7E and data not shown). These results
suggest that E1 induces a DNA damage response and concom-
itant activation of the ATM pathway.
FIG. 6. Nuclear accumulation of enzymatically active E1 induces a DNA damage response. (A) The indicated EYFP and EYFP-E1 wild-type
or mutant proteins were transiently expressed in C33A cells. Twenty-four hours posttransfection, cells were fixed and stained for phospho-serine
139 of H2AX. Mounted cells were then visualized by 20 confocal fluorescence microscopy. Mock-transfected cells and cells treated for 24 h with
50 M etoposide (Eto.) were used as negative and positive controls, respectively. (B) Analysis similar to that for panel A but using the E1 fragments
described in the legend for Fig. 2.
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H2AX foci are induced in cells containing low levels of
nuclear E1. In experiments such as those presented above, we
consistently observed that H2AX was present throughout the
nucleus of E1-expressing cells (pan-nuclear staining) rather
than being localized into the punctuated nuclear foci that are
a hallmark of DNA double-strand breaks (DSBs). We rea-
soned that this pan-nuclear staining was in part a consequence
of the amount of E1 being expressed in these cells and, ac-
cordingly, that nuclear foci may become apparent in cells ex-
pressing lower levels of E1. To investigate this possibility, we
made use of an E1 mutant carrying a defective cyclin-binding
motif (CBM). This mutant accumulates only at low levels in
the nucleus because it is subject to rapid Crm1-dependent
nuclear export (23). As anticipated, we observed by fluores-
cence microscopy that the activation of H2AX was barely
detectable in E1 CBM-expressing cells, especially when visu-
alized at magnification 20 (Fig. 8A). At magnification 63,
we were able to detect that the low levels of H2AX in these
FIG. 7. The ability of E1 to induce a DDR is a conserved feature of papillomavirus E1 and involves activation of the ATM pathway. (A) The
ability of E1 to induce a DDR is conserved in HPV31, -16, and -11 and BPV E1. The activation of H2AX was analyzed in C33A cells expressing
the indicated GFP or GPF-E1 proteins. To analyze H2AX activation, cells were fixed 24 h posttransfection, stained for phosphoserine 139 of
H2AX, mounted, and visualized by 20 fluorescence confocal microscopy. (B) Expression of E1 over time correlates with activation of H2AX.
The EYFP-E1 wild type was transiently expressed in C33A cells. Six and twelve hours posttransfection, cells were analyzed as described for panel
A. (C to E) E1 activates components of the ATM pathway. The indicated EYFP or EYFP-E1 wild-type or mutant proteins were transiently
expressed in C33A cells. Twenty-four hours posttransfection, cells were fixed and stained for phosphoserine 1981 of ATM (pATM) (C),
phosphothreonine 68 of Chk2 (pChk2) (D), or phosphoserine 345 of Chk1 (pChk1) (E). Mock-transfected cells were used as negative controls,
and cells treated for 24 h with 50 M etoposide (Eto.) or 2 mM hydroxyurea (HU) were used as positive controls.
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cells were localized into discrete nuclear foci (Fig. 8B). This
was in contrast to the high levels of H2AX observed at mag-
nification 20 and the pan-nuclear staining observed at mag-
nification 63 in cells expressing wild-type E1 (Fig. 8A and B).
Furthermore, we determined that increasing the amounts of
the E1 CBM mutant in the nucleus by treatment of the cells
with leptomycin B to inhibit its Crm1-dependent nuclear ex-
port resulted in pan-nuclear H2AX staining (Fig. 8A and B).
These results indicate that the levels of nuclear E1 affect the
pattern of H2AX staining in cells and suggest that H2AX
first accumulates in discrete foci and later progresses to pan-
nuclear staining as the amount of nuclear E1 increases. Fur-
thermore, the accumulation of H2AX in discrete nuclear foci
raises the possibility that E1 induces a DDR by creating DSB
in the host genome (see Discussion).
The E1-induced DDR is attenuated by E2. The results pre-
sented so far indicate that E1 expression triggers a robust
DDR. To test if a similar DDR would be induced under viral
DNA replication conditions, we investigated if E2, with or
without a plasmid containing the viral origin (ori), had any
effect on the levels of H2AX induced by EYFP-E1. First, we
confirmed that the levels of H2AX could be accurately mea-
sured by flow cytometry. As can be seen in Fig. 9 (top row), the
amounts of H2AX were found to be 2.7-fold higher in cells
expressing low levels of E1 than in control cells (EYFP-E1-
FIG. 8. H2AX staining is punctuated in cells that accumulate low
levels of E1 in their nucleus. The activation of H2AX in cells tran-
siently expressing EYFP-E1, either wild type (WT) or a cyclin-binding
motif mutant derivative (CBM), was analyzed by immunofluorescence
confocal microscopy 24 h posttransfection. Where indicated, the E1
CBM-expressing cells were treated with 7.5 ng/ml of leptomycin B
(LMB) for 4 h. Detection of H2AX was performed at a magnification
of 20 (A) or 63 (B).
FIG. 9. E2 and the viral origin attenuate the E1-induced DDR.
H2AX levels in cells transiently expressing wild-type EYFP-E1 or the
NES/ATPase mutant derivative, with or without E2, and containing or
lacking the viral origin, are indicated. H2AX levels were quantified by
flow cytometry. For each sample, H2AX levels were determined as a
function of EYFP-E1 expression (low-, medium-, or high-EYFP-E1-
expressing cells; shaded histograms), and the non-EYFP-expressing
cells of the same cell population were used as an internal control (open
histograms). For each condition, the fold increase in H2AX activa-
tion is indicated in the upper right corner and was obtained by dividing
the average value of activation measured for the EYFP-E1-positive
cells by that of the controls cells.
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negative cells of the same transfected cell population) and up
to 7.6-fold higher in those expressing high levels of E1. These
results confirmed that the levels of H2AX increase as a func-
tion of E1 expression. Furthermore, this effect was specific to
wild-type E1, since only low levels of H2AX were detected in
cells expressing the E1 NES/ATPase mutant protein (Fig. 9,
second row). We then used this method to quantify the effect
of E2 and the viral origin on E1-induced H2AX activation.
Specifically, we cotransfected C33A cells with a vector express-
ing EYFP-E1 with or without a plasmid encoding E2 and one
containing the origin, in the same ratios as those used in our
standard transient DNA replication assay. We also cotrans-
fected increasing amounts of E2 or E2 plus the origin at levels
2-, 4- and 8-fold higher than those used in the DNA replication
assay in order to favor complex formation between E1 and E2.
Only the results obtained under standard replication condi-
tions (1) and those obtained with an 8-fold excess (8) of E2
in the presence or absence of the origin are presented in Fig.
9. These experiments revealed that the E1-induced activation
of H2AX decreased as a function of the amount of E2 and
origin transfected (compare 1 and 8 in Fig. 9). At 8 E2
and ori, the activation of H2AX was reduced close to back-
ground levels, even in cells expressing high levels of EYFP-E1.
Results obtained with intermediate amounts of E2 (2 and
4) indicated that its inhibitory effect on H2AX induction
was dose dependent (data not shown). E1-induced H2AX
levels were decreased by E2 alone in the absence of the origin
but not by the origin alone (Fig. 9). This effect of E2 was found
to be dependent on its interaction with E1, since it was dimin-
ished by the E39Q substitution in E2, which reduces its ability
to interact with E1 and to support transient DNA replication
by approximately 50 to 60% under our standard assay condi-
tions (24; data not shown). Finally, we confirmed by confocal
microscopy that the induction by E1 of pChk2, a downstream
effector of the ATM pathway, is also attenuated by E2 (data
not shown). Collectively, the aforementioned results indicate
that E2 significantly reduces, but does not completely elimi-
nate, the E1-induced DDR.
Cells expressing E1 and E2 are arrested in very early S
phase. The finding that E2 attenuates the E1-induced DDR
prompted us to investigate if it could also alleviate the S-phase
arrest caused by E1. To do so, we performed the same exper-
iments as above with a gradient of E2, with or without the
origin, but this time monitored both cell cycle progression and
DNA synthesis. Cells were transfected with E1 and increasing
amounts of E2 or E2 plus ori and, 24 h later, tested for their
ability to carry out DNA synthesis, using a 1-h pulse with
BrdU. BrdU incorporation was then plotted as a function of
the cell cycle as previously described (Fig. 5C), and the per-
centages of cells in G1, S, and G2 were quantified using the
gates shown for the mock-transfected cells in Fig. 10A. Quan-
tification was performed on cells transfected with 1 and 8
E2 (Fig. 10A), with or without the ori, and numbers obtained
are presented in the histogram of Fig. 10B (upper panel).
From this analysis, we determined that E2 but not the origin
alone leads to a dose-dependent accumulation of E1-express-
ing cells in G1 (blue arrow in Fig. 10B) and a concomitant
decrease of cells in S phase (red arrow). Note that we show in
the following section that cells expressing E1 and increasing
amounts of E2 can still replicate the ori-containing plasmid.
Since HPV DNA replication requires host DNA replication
factors, this is consistent with these cells being arrested in S
phase rather than in G1. Given this result and the fact that the
flow cytometry analysis cannot distinguish between cells in G1
from those in very early S, it is likely that cells expressing E1
and E2 are arrested very early in S phase, close to the G1/S
boundary, rather than in G1 per se.
In similar experiments, we found that the ability of E1 and
FIG. 10. E2 and the viral origin modulate the E1-induced cell cycle
arrest. BrdU incorporation in EYFP-E1-expressing cells throughout
the cell cycle. (A) Scatter plots obtained with cells transfected with a
wild-type E1 expression vector, either alone or together with two
different amounts (1 and 8) of wild-type or E39Q E2 expression
vector and the origin, as indicated. BrdU incorporation and DNA
content were determined by flow cytometry. (B) Proportions of cells in
G1, S, and G2 were quantified from the samples shown in panel A and
from those transfected with a plasmid expressing the EYFP-E1 NES/
ATPase mutant protein as a control (data not shown). Gates showed
for the mock-transfected sample were used to quantity the cell cycle
distribution of each sample, and the results were reported in a histo-
gram. Results obtained with cells expressing EYFP-E1 are shown in
the upper panel, while those obtained with cells expressing the NES/
ATPase mutant E1 are shown in the lower panel. The blue and red
arrows highlight the concomitant changes in the proportions of cells in
G1 and S phase, respectively, brought about by increasing amounts of
E2 with or without the origin. (C) CFA performed with 3F-HPV31 E2
or with 3F-HPV31 E1 expression vector. Cells were selected in G418-
containing medium before staining.
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E2 to cause cell cycle arrest in G1/very early S was slightly
enhanced in the presence of the origin and, importantly, that
this was not observed with the E39Q E2 mutant (Fig. 10B).
This last result suggested that cell cycle arrest in G1/very early
S phase is dependent on complex formation between E1 and
E2 and by inference that it is not caused by E2 alone. To
substantiate the notion that E2 is not sufficient to cause this
cell cycle arrest, we determined the effect of wild-type E2 in
cells expressing an E1 NES/ATPase mutant that does not in-
terfere with cell cycle progression. As anticipated, only 10% of
the cells expressing E2 and the mutant E1 accumulated in G1
(Fig. 10B, lower panel, and data not shown). Importantly, and
in contrast to the results obtained with wild-type E1, this weak
cell cycle inhibitory effect was also observed with E39Q E2
(Fig. 10B), suggesting that it was independent of complex for-
mation between E1 and E2. From these results, we conclude
that E2 has only a modest effect on cell cycle progression, a
result supported by the observation that it does not prevent
cellular proliferation in a colony formation assay (Fig. 10C).
Collectively, the results presented above indicate that complex
formation between E1 and E2 causes cells to arrest in G1/very
early S. The evidence supporting the hypothesis that E1- and
E2-expressing cells are arrested in very early S rather than in
G1 is presented below.
Transient HPV DNA replication neither requires nor is af-
fected by a DDR. The results presented in Fig. 9 and 10 indi-
cated that E2, when expressed in large amounts, reduces the
DDR caused by E1 to almost background levels and causes an
accumulation of E1-expressing cells in G1/very early S phase.
To determine if these effects would impinge on viral DNA
replication, we set out to test the effect of increasing amounts
of E2 and the origin on E1-catalyzed DNA replication, using
our luciferase assay (24).
First, we used confocal fluorescence microscopy to examine
the intracellular localization of EYFP-E1 under our standard
DNA replication assay conditions or in the presence of an
8-fold excess of E2 and the origin. Under standard conditions,
we confirmed that E1 is localized primarily into large nuclear
foci (Fig. 11A), as previously reported (23, 78). When E2 and
the ori were present in excess, EYFP-E1 was still localized into
nuclear foci but of a smaller size. Whether these smaller foci
form in G1 and become larger during S phase is under inves-
tigation. Importantly, we confirmed that H2AX was strongly
induced under standard DNA replication conditions and sig-
nificantly reduced in the presence of excess E2 and ori, as
anticipated from the flow cytometry quantification showed in
Fig. 9. Interestingly, we noted that part of the remaining
H2AX signal observed at 8 was localized within these foci
(Fig. 11A). Next, we performed the luciferase DNA replication
assay in cells transfected with a constant and limiting amount
of EYFP-E1 and a 1-, 2-, 4-, or 8-fold excess of E2 and the ori.
As controls, the same conditions were used in the absence of
E2 to prevent DNA replication. As expected, these control
transfections gave rise to increasingly higher Fluc/Rluc ratios
proportional to the amount of transfected ori plasmid (which
contains the cytomegalovirus (CMV)-Fluc reporter gene) but
they did not increased at 48 and 72 h posttransfection, con-
firming the lack of replication (Fig. 11B, “No E2”). In contrast,
the levels of transient DNA replication in cells expressing E1
and E2 gradually increased over time, even in the presence of
an excess of E2 and ori (Fig. 11B, E2 WT). Thus, viral DNA
replication can take place in E1-expressing cells containing an
excess of E2 and ori, indicating that these cells must be in very
early S phase rather than late G1 and furthermore that viral
FIG. 11. Effect of increasing amounts of E2 and the origin on
E1-catalyzed DNA replication. (A) Activation of H2AX in cells
transfected with an EYFP-E1 expression plasmid and two different
amounts (1 and 8) of wild-type E2 expression vector plus the
origin. Twenty-four hours posttransfection, E1-expressing cells were
fixed, stained for H2AX, mounted, and visualized by 40 fluores-
cence confocal microscopy. (B) Transient DNA replication activity of
E1 in the presence of increasing amounts of E2 and the origin. DNA
replication activity of EYFP-E1 was determined 24, 48, and 72 h
posttransfection. Cells were transfected with 5 ng of EYFP-E1 expres-
sion plasmid and increasing amounts of wild-type E2 expression vector
plus the origin (E2 WT), as indicated (1, 2, 4, and 8). Back-
ground signal was measured in the absence of E2 (5 ng of E1 and
increasing amounts of ori-plasmid) (No E2) or in the absence of E1
(No E1). Replication activities are reported as Fluc/Rluc ratios, and
error bars represent standard deviations. (C) Effect of the ATM kinase
inhibitor KU-55933 on viral DNA replication. Transient HPV DNA
replication assays were performed under standard conditions (1) or
in the presence of an excess of E2 and the origin (8). KU-55933 (KU)
was tested at increasing concentrations ranging from 0.156 to 10 M.
Gemcitabine (Gemci., from 1.56 to 100 nM) and 0.1% dimethyl sul-
foxide (DMSO) were used as positive and negative controls, respec-
tively. DNA replication levels (Fluc/Rluc ratios) from which back-
ground signals were subtracted are reported as percentages of the
activity measured in the presence of DMSO, which was set at 100%.
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DNA replication occurs independently of a robust DDR
(which is attenuated by high concentrations of E2). To ascer-
tain the latter suggestion, we tested the effect of an ATM
inhibitor (KU-55933) on transient DNA replication. This in-
hibitor had only a weak effect on HPV DNA replication, at
concentrations up to 10 M, in contrast to the nucleotide
analog gemcitabine, which was used as a positive control (Fig.
11C). The inhibitory activity of KU-55933 was confirmed by
monitoring its effect on the phosphorylation of Thr68 of Chk2,
a well-established ATM phosphorylation site (data not shown).
Collectively, these findings indicate that HPV DNA replication
not only occurs independently of a robust DDR (at high con-
centrations of E2 and ori) but remarkably that it remains
unabated in the face of a DDR and checkpoint response (at
low concentrations of E2 and ori), as demonstrated recently by
King et al. (39).
Keratinocytes expressing an NES-defective E1 mutant ge-
nome show increased levels of H2AX. We previously reported
that a mutant HPV31 genome encoding NES-defective E1 is
poorly maintained as an episome in immortalized keratino-
cytes and is gradually lost upon cellular division (i.e., upon
several cell passages). This and other results, including those
presented herein, led us to suggest that nuclear accumulation/
retention of the NES E1 mutant protein is detrimental to
cellular proliferation. Since we show here that this antiprolif-
erative effect of E1 is accompanied by a DDR, we set out to
determine if a similar DDR was induced in keratinocytes con-
taining the E1 NES mutant genome. To do so, we compared
the levels of H2AX in keratinocytes immortalized with the
mutant genome or wild-type HPV31, using immortalized cells
at an early passage in which the E1 NES mutant genomes is
still maintained as an episome, albeit in smaller amounts (23).
As can be seen in Fig. 12, higher levels of H2AX were indeed
induced by the E1 NES mutant as compared to results for the
wild type, thus confirming that high levels of E1 in the nucleus
are sufficient to induce a DDR. Thus, under physiological
conditions, the nuclear export of E1 serves to prevent the
induction of a DDR in undifferentiated keratinocytes.
DISCUSSION
In this article, we report that the antiproliferative activity of
E1 is conserved in HPV11, -31 and -16 and in bovine papillo-
mavirus (BPV) and that it requires the origin-binding and
ATPase activities of the protein. We provide evidence that E1
induces a cell cycle arrest independently of the viral oncogenes
E6 and E7, since the block was also detected in HeLa cells, and
independently of p53, since it was observed in cells that express
either wild-type (U2OS) or R275C mutant (C33A) p53 (15,
16). Furthermore, we have shown that the arrest takes place
during the early events of S phase, when BrdU is incorporated
into DNA and when PCNA has not yet assembled into large
foci. Interestingly, this arrest is accompanied by the induction
of a DDR and the activation of the ATM pathway, since
E1-expressing cells exhibit elevated levels of H2AX, pATM
Ser1981, and pChk2 Thr68. We also show that complex for-
mation between E1 and E2 reduces the levels of H2AX in-
duced by E1 and leads to a redistribution of E1-expressing cells
to an earlier part of S phase, close to the G1/S boundary.
Importantly, we present evidence that transient viral DNA
replication is neither affected by nor dependent on a DDR.
The biological significance of these findings is highlighted by the
observation that keratinocytes immortalized with an HPV31 ge-
nome encoding an NES mutant E1 show drastically higher
levels of H2AX than cells maintaining a wild-type episome,
suggesting that nuclear export of E1 is indeed required to
alleviate the activation of a DDR in infected cells.
Induction of a cell cycle arrest and activation of a DDR by
E1. In a recent article (23), we reported that sustained accu-
mulation of E1 in the nucleus is detrimental to cellular prolif-
eration. Here we have shown that E1 induces a cell cycle block
in early S phase that is accompanied by the induction of a
DDR and that both events require the highly conserved origin-
binding and ATPase activities of E1. Accordingly, we found
that E1 from low-risk (HPV11) and high-risk (HPV31 and -16)
HPV types and from BPV were all able to induce cell cycle
arrest, inhibit cellular proliferation, and induce a DDR (albeit
to different extents) (Table 4).
We previously showed that an HPV11 E1 fragment compris-
ing the OBD and C-terminal ATPase domain is sufficient to
replicate DNA in vitro, indicating that it can assemble into a
functional helicase (2). In this study, the findings that an anal-
ogous fragment of HPV31 E1 has antiproliferative activity and
supports low levels of transient DNA replication raise the
possibility that E1 can assemble onto host DNA and unwind it
nonspecifically. This nonspecific unwinding activity may ac-
count for the ability of E1 to induce cell cycle arrest and a
TABLE 4. Activation of H2AX by E1 from different papillomaviruses







a The activation of H2AX in cells expressing the indicated GFP fusion pro-
tein was analyzed by flow cytometry as described in the legend for Fig. 9.
FIG. 12. H2AX activation in keratinocytes immortalized with a
wild-type or E1 NES mutant genome. Early-passage keratinocytes
immortalized with the indicated HPV31 genome were fixed and
stained with an antibody against H2AX. Nuclei (DNA) were stained
with DAPI.
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concomitant DDR. These effects appear to be specific to E1,
however, since they were not observed with the related large
T-antigen helicase from SV40, whose origin-binding and
ATPase domains are structurally and functionally similar to those
of E1 (11, 20, 21, 43, 47). Indeed, we observed that large T
antigen was unable to interfere with cellular proliferation in a
CFA and induced only low levels of DDR markers compared
to results for E1 (data not shown). One of the main differences
between E1 and large T antigen is that the former has a higher
nonspecific DNA-binding activity, at least in vitro (80, 83; A.
Fradet-Turcotte and J. Archambault, unpublished results). Ac-
cordingly, it has been reported that E1 is capable of replicating
a DNA template that does not contain the viral origin (8),
indicating that it can efficiently bind and unwind nonviral
DNA. These observations further support the possibility that
E1 can unwind host DNA nonspecifically, thus accounting for
its capacity to interfere with cell cycle progression and to in-
duce a DDR. Consistent with this hypothesis, we found that
the formation of a complex between E1 and E2, which has
been reported to inhibit the nonspecific DNA-binding activity
of E1 (8, 67, 73), greatly reduces its capacity to induce a DDR
(Fig. 9). However, the fact that E2 did not prevent E1-induced
cell cycle arrest suggests either that E2 does not reduce the
magnitude of the DDR below the threshold necessary to in-
duce cell cycle arrest or alternatively that the ability of E1 to
induce a DDR and to inhibit cell cycle progression are two
mechanistically distinct events. In support of the latter possi-
bility, we observed in CFAs that E1 inhibits the proliferation
of ATM-deficient cells (data not shown), indicating that this
growth-inhibitory effect is independent of the activation of the
ATM kinase. Similarly, we observed that the ability of E1 to
block C33A cells in S phase is not prevented by treatment with
the ATM inhibitor KU-55933 (data not shown).
Possible mechanisms by which E1 blocks cell cycle progres-
sion. Although the exact mechanism by which E1 interferes
with cell cycle progression remains unknown, several hypoth-
eses can be drawn from the existing literature. For instance,
the depletion of cellular DNA replication factors or of com-
ponents of the origin-firing machinery by small interfering
RNA (siRNA) has been shown to arrest the progression of the
cell cycle in S phase (51, 55, 79, 89). Given that the OBD and
ATPase domain of E1, which are required to induce cell cycle
arrest, have been reported to interact with the polymerase
-primase, topoisomerase I, and RPA (reviewed in reference
77), it is possible that E1, by competing for these factors,
makes them unavailable for host DNA synthesis. Alternatively
or in addition, E1 may also interfere with the firing of host
origins in early S phase, as previously reported for the Rep78
helicase from adeno-associated virus (AAV) (7). Rep78 has
been suggested to interfere with cell cycle progression by in-
teracting with Cdc25A and inhibiting its phosphatase activity,
which is required for the firing of origins (7, 66). Interestingly,
Rep78 also induces a DDR which, similar to that caused by E1,
is not sufficient to block cell cycle progression. However, if
Cdc25A was inactivated by E1, we would anticipate that Cdk2,
a well-characterized Cdc25A substrate, would also be inactive
and thus unable to phosphorylate E1 and prevent its nuclear
export. The finding that E1 is nuclear in E1-arrested cells
indicates that it has been phosphorylated by Cdk2, and we
surmise that Cdc25A must be active in these cells. Therefore,
while it is possible that E1 sequesters Cdc25A away from the
origin firing complexes, it is unlikely that it inhibits its phos-
phatase activity. Whether E1 interacts with Cdc25A or other
proteins, such as CDC45 and Dbf4/cdc7 (reviewed in reference
66), which are also required for the firing of host origins,
remains to be investigated.
Possible mechanisms by which E1 induces a DDR. We have
shown that activation of H2AX occurs soon after the expres-
sion of E1 and can be prevented by high concentrations of E2.
Typically, the activation of H2AX and of the ATM pathway is
triggered by double-stranded breaks (DSBs) in the host DNA
and by the activation of cell cycle checkpoints (reviewed in
reference 4). As our results demonstrate, induction of a DDR
is dependent on the origin-binding and ATPase activities of E1
and can be reduced by E2, consistent with the nonspecific
unwinding of host DNA by E1 being a source of DSBs. In
addition to causing DSBs, it is possible that E1 triggers a DDR
by interacting directly with components of the DNA repair
machinery, such as the MRN complex, whose Mre11, Rad50,
and Nbs1 subunits colocalize with HPV18 and -11 E1 in cells
(35; Thomas Broker, personal communication). Indeed, it has
recently been shown that the tethering of these proteins to
DNA is sufficient to induce a DDR in the absence of DSB (71).
Activation of H2AX in defined nuclear foci is considered a
hallmark of DSBs, whereas its pan-nuclear activation has been
associated with apoptosis during S phase (17). Our results with
an E1 CBM mutant suggest that both phenomena can happen
in E1-expressing cells depending on the nuclear levels of E1.
Indeed, we found that in cells expressing the E1 CBM mutant,
which accumulates only at low levels in the nucleus and does
not arrest cell cycle progression (23), H2AX is localized in
discrete nuclear foci. Furthermore, when the nuclear accumu-
lation of this E1 mutant was increased by inhibiting its nuclear
export using leptomycin B (LMB) or by inhibiting its NES,
H2AX staining became pan-nuclear (Fig. 8 and data not
shown). On the basis of these observations, we propose that
the accumulation of H2AX in discrete nuclear foci results
from the induction of DSB by low levels of E1 in the nucleus,
whereas its pan-nuclear accumulation observed at higher E1
concentrations arises from the accumulation of such foci com-
bined with the cells being permanently arrested in S phase and
possibly undergoing apoptosis.
Activation of an ATM-dependent DDR is not required for
transient HPV DNA replication. An ATM-dependent DDR is
activated by many double-stranded DNA viruses, for different
reasons. For example, similarly to HPV, Epstein-Barr virus
(EBV) activates the ATM pathway but does not rely on its
activation to replicate its genome (41). In contrast, the activa-
tion of ATM is required for the phosphorylation of SV40 large
T antigen and for the efficient replication of viral DNA (69).
Kadaja et al. (35) reported that replication of integrated HPV
genomes by E1 and E2 leads to the induction of the ATM
pathway and, to a lesser extent, of the ATR pathway and to the
recruitment of ATM, Chk2, ATRIP, pChk1, Ku70/80, and the
MRN complex at these integration sites. In this study, we
found that E1 is sufficient to activate the ATM pathway re-
gardless of the presence or the absence of the genome, sug-
gesting that the induction of the ATM pathway reported by
Kadaja et al. (35) may have been caused at least in part by E1.
Although E1 activates the ATM pathway, viral DNA replica-
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tion does not require the induction of this DDR nor is affected
by it. These findings are in agreement with those of King et al.
(39), who showed that replication of an HPV origin-containing
plasmid by E1 and E2 from HPV11 and -16 is not affected by
treatment of the cells with 50 M etoposide during 24 h.
Finally, our observation that HPV DNA replication can occur
independently of the activation of the ATM pathway is con-
sistent with the previous observation by one of our groups
(C.A. Moody and L.A. Laimins) that maintenance of the
HPV31 episome in immortalized keratinocytes is unaffected by
the ATM inhibitor KU-55933 (53). In that same study, it was
found that despite being unnecessary for genome mainte-
nance, the ATM pathway is required for amplification of the
viral episome in differentiated keratinocytes, in part to induce
the activity of caspase-3/7 and proteolytic cleavage of the N-
terminal domain of E1 (52, 53). This study also showed that
activation of the ATM-dependent DDR in differentiating ke-
ratinocytes immortalized with the HPV31 genome was depen-
dent on E6 and E7, suggesting that viral oncogenes contribute
significantly to the activation of this pathway during amplifica-
tion of the viral genome (53).
Although our first observation that nuclear accumulation of
E1 leads to the activation of a DDR was made with transfected
cells under conditions where E1 is expressed at high levels, a
similar DDR activation was observed in immortalized kerati-
nocytes expressing an NES mutant E1 from the HPV31 epi-
some. As such, these results suggest that the accumulation of
E1 in the nucleus of infected cells is sufficient to induce a
DDR. Since nuclear accumulation of E1 has been shown to be
detrimental to cellular proliferation, our findings are consistent
with a model where sustained accumulation of E1 in the nucleus
induces an S-phase arrest, which in turn induces apoptosis (pan-
nuclear H2AX). Consistent with this model, Jolly et al. recently
reported that leptomycin B, which inhibits the Crm1-exportin
pathway, essential for the nuclear export of E1 (23), increases
apoptosis in a cell line maintaining the HPV16 episome (34).
Collectively, our study suggests that both the nuclear accu-
mulation and the nonspecific DNA unwinding activity of E1
need to be tightly regulated by the nuclear export of E1 and by
its interaction with E2, respectively, in order to avoid the pre-
mature activation of the ATM pathway in undifferentiated
keratinocytes. Failure to adequately control the nuclear accu-
mulation and activity of E1 in the lower layers of an infected
epithelium may lead to the induction of undesired DNA breaks
in the host genome that are recombinogenic and could favor
integration of the viral genome. This in turn would increase the
probability of generating integration events that disrupt the E2
open reading frame and lead to overexpression of the viral E6
and E7 proteins. For lesions containing high-risk HPVs but not
for those associated with low-risk types, such integration events
represent a critical risk factor for progression to cancer. Thus,
failure to properly regulate the nuclear accumulation and activity
of E1 from high-risk HPV types may be a more important con-
tributor to HPV-induced carcinogenesis than previously sus-
pected.
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